Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

December 31, 2005

Conditions
Chronic Shift Work Sleep Disorder
Interventions
DRUG

PROVIGIL 200 mg

PROVIGIL 200 mg/day

DRUG

Armodafinil 250 mg

Armodafinil 250 mg/day

DRUG

Armodafinil 200 mg

Armodafinil 200 mg/day

DRUG

Armodafinil 150 mg

Armodafinil 150 mg/day

DRUG

Placebo

Matching placebo tablets

Trial Locations (20)

10025

Clinilabs / Sleep Disorders In, New York

15221

Consolidated Clinical Trials, Pittsburgh

20815

Center for Sleep/Wake Disorder, Chevy Chase

27612

Wake Research Associates, Raleigh

29201

SleepMed of South Carolina, Columbia

30342

Neurotrials Research, Atlanta

31202

SLEEPMED, Inc., Macon

43608

St. Vincent Mercy Medical Cent, Toledo

60093

Henry Lahmeyer, MD, Northfield

66211

Vince and Associates Clinical, Overland Park

71913

Central Arkansas Research, Hot Springs

84107

Radiant Research Salt Lake, Salt Lake City

85050

Psypharma Clinical Research, Phoenix

85712

PsyPharma Clinical Tucson, Tucson

89104

Clinical Rsch Center of Nevada, Las Vegas

90048

Pacific Sleep Medicine Service, Los Angeles

92121

Pacific Sleep Medicine Service, San Diego

92123

BMR HealthQuest, San Diego

94305

Stanford University, Stanford

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00236080 - Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL | Biotech Hunter | Biotech Hunter